Ranibizumab or Bevacizumab in Patients With Neovascular AMDRanibizumab or Bevacizumab in Patients With Neovascular AMD
Is there a particular anti-VEGF agent that works best in neovascular AMD? This new study compares ranibizumab and bevacizumab. The British Journal of Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 29, 2013 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
NCI Grantees Receive Breakthrough Prizes in Life Sciences
The Breakthrough Prize in Life Sciences recognizes “excellence in research aimed at curing intractable diseases and extending human life.” The inaugural set of prizes, awarded in February 2013 by a not-for-profit corporation dedicated to advancing breakthrough research, are backed by well-known personalities such as Sergey Brin, Google co-founder and his wife, Anne Wojcicki, co-founder of a personal genomics and biotech company 23andMe; Facebook founder Mark Zuckerberg and his wife, Priscilla Chan; Russian entrepreneur Yuri Milner; and Art Levinson, chairman of Apple and Genentech.
The 11 recipients will each rece...
Source: NCI Benchmarks - March 8, 2013 Category: Cancer & Oncology Authors: Aleea Farrakh Khan Tags: Scientist Spotlight award Source Type: news
NICE backs drug for diabetic macular oedema
The National Institute for Health and Clinical Excellence has recommended ranibizumab (Lucentis) for treating visual impairment caused by diabetic macular oedema, after its manufacturer Novartis agreed to provide it at a discounted rate. (Source: Nursing Times Breaking News)
Source: Nursing Times Breaking News - March 1, 2013 Category: Nursing Source Type: news
NICE costing template for its guidance on ranibizumab for diabetic macular oedema (TA 274)
Source: NICE
Area: News
NICE has published a costing statement to accompany its guidance on the use of ranibizumab for treating visual impairment due to diabetic macular oedema (TA 274).
The costing report calculates that: "the annual cost associated with implementing this recommendation is estimated as £41,000 for a population of 100,000 based on the standard assumptions in the model once a steady state is reached. There are also anticipated to be non-recurrent costs from treating the prevalent population on implementation of the guideline of around £341,000. It is assumed that people with eligible eyes will...
Source: NeLM - News - February 27, 2013 Category: Drugs & Pharmacology Source Type: news
NICE issues final guidance supporting the use of ranibizumab for diabetic macular oedema (TA 274)
Source: NICE
Area: Evidence > Guidelines
NICE has issued final guidance (TA 274) supporting the use of ranibizumab for treating visual impairment due to diabetic macular oedema (DMO) only if:
. the eye has a central retinal thickness of 400 micrometres or more at the start of treatment and
. the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).
NICE conducted a rapid review of the original guidance (TA 237; November 2011) because the manufacturer submitted a revised Patient Access Scheme, together with updated analyses showi...
Source: NeLM - Guidelines - February 27, 2013 Category: UK Health Source Type: news
Phase III study: Twelve-Month comparison of 0.5 mg or 2.0 mg ranibizumab in patients with wet age-related macular degeneration (HARBOR)
Source: Ophthalmology
Area: News
Several small studies have suggested the potential of enhanced efficacy with higher 2mg dosing of ranibizumab. The HARBOR study was a 24-month, phase III, randomised, multicentre, double-masked study which evaluated the 12-month efficacy and safety of intravitreal ranibizumab 0.5 mg and 2.0 mg administered monthly and on an as-needed (PRN) basis in treatment-naïve patients (n=1,098) aged over 50 years with subfoveal neovascular age-related macular degeneration (wet AMD).
Noninferiority (NI) tests with a prespecified NI margin of 4 letters comparing the 0.5 mg PRN with the 0.5 ...
Source: NeLM - News - February 6, 2013 Category: Drugs & Pharmacology Source Type: news
Little Help from Lucentis for Vitreous Hemorrhage (CME/CE)
(MedPage Today) -- Patients with vitreous hemorrhage related to diabetic retinopathy derived minimal short-term benefit from treatment with the angiogenesis inhibitor ranibizumab (Lucentis), results of a randomized trial showed. (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - February 5, 2013 Category: Opthalmology Source Type: news
Little Help from Lucentis for Diabetic Eyes (CME/CE)
(MedPage Today) -- Patients with vitreous hemorrhage related to diabetic retinopathy derived minimal short-term benefit from treatment with the angiogenesis inhibitor ranibizumab (Lucentis), results of a randomized trial showed. (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - February 1, 2013 Category: Opthalmology Source Type: news
Ranibizumab Fails to Beat Saline in Avoiding VitrectomyRanibizumab Fails to Beat Saline in Avoiding Vitrectomy
Patients with vitreous hemorrhage from proliferative diabetic retinopathy who received intravitreal injections of ranibizumab or saline had about the same rates of vitrectomy by 16 weeks. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2013 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
NETAG issues appraisal and recommendation on aflibercept for AMD
Source: NETAG
Area: Evidence > Drug Specific Reviews
The NHS North East Treatment Advisory Group (NETAG) has undertaken an appraisal of aflibercept (Eylea®) within its licensed indication for the management of neovascular (wet) age-related macular degeneration (AMD). The Group recommends its use, within its licensed indication, for the treatment of newly diagnosed and untreated wet AMD. It does not however recommend its use for the same episode of AMD refractory to treatment with other biological therapies such as ranibizumab. This recommendation is contingent on a maximum cost per aflibercept dose as stated in the ...
Source: NeLM - Drug Specific Reviews - January 21, 2013 Category: Drugs & Pharmacology Source Type: news
NICE makes u-turn decision on Lucentis
A UK health watchdog has recommended the use of Lucentis for the treatment of visual impairment caused by diabetic macular oedema (DMO) after manufacturer Novartis dropped the price of the drug. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 7, 2013 Category: Pharmaceuticals Source Type: news
